Fredun Pharmaceuticals Ltd
BSE:539730
Fredun Pharmaceuticals Ltd
BSE:539730
Price:
1 686.3
INR
2.15%
Market Closed
Market Cap:
₹9.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Fredun Pharmaceuticals Ltd
BSE:539730
|
IN |
|
Purifloh Ltd
ASX:PO3
|
AU |
|
N
|
Ngan Son JSC
VN:NST
|
VN |
|
Abundante Ltd
SGX:570
|
SG |
|
P
|
Protalix Biotherapeutics Inc
AMEX:PLX
|
US |
|
United States Lime & Minerals Inc
NASDAQ:USLM
|
US |
|
C
|
CI Banco SA Institucion de Banca Multiple FF/00939
BMV:TERRA13
|
MX |
|
Grainger PLC
LSE:GRI
|
UK |
|
Caspian Sunrise PLC
LSE:CASP
|
UK |
|
N
|
Notoria Serwis SA
WSE:NTS
|
PL |
|
Cuentas Inc
OTC:CUEN
|
US |
|
B
|
BAE Systems PLC
XETRA:BSP
|
UK |
|
P
|
Peugeot Invest SA
LSE:0HV8
|
FR |
|
Manorama Industries Ltd
NSE:MANORAMA
|
IN |
Relative Value
The Relative Value of one
FREDUN
stock under the Base Case scenario is
hidden
INR.
Compared to the current market price of 1 686.3 INR,
Fredun Pharmaceuticals Ltd
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
FREDUN Relative Value
HIDDEN
Multiples Across Competitors
FREDUN Competitors Multiples
Fredun Pharmaceuticals Ltd Competitors
Fredun Pharmaceuticals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Fredun Pharmaceuticals Ltd
BSE:539730
|
9.1B INR | 1.5 | 25.2 | 11.6 | 11.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
860.3B USD | 13.2 | 41.7 | 28.1 | 30 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.9B USD | 6 | 21.1 | 14.7 | 18.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 3.9 | 18.8 | 11.2 | 12.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.1B GBP | 4.9 | 28 | 15.6 | 21.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.3B USD | 4.4 | 15.7 | 9.7 | 11.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 5.1 | 20.6 | 12.8 | 16.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.4 | 10.4 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.2B USD | 2.4 | 19.6 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
114.7B USD | 2.4 | 16.3 | 6.9 | 8.5 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
